Discovery and validation of urinary biomarkers for detection of renal cell carcinoma

Journal of Proteomics

Volumn 98, Issue , 2014, Pages 44-58

  Frantzi, Maria ^a,b   Metzger, Jochen ^a   Banks, Rosamonde E ^c   Husi, Holger ^d   Klein, Julie ^a   Dakna, Mohammed ^a   Mullen, William ^d   Cartledge, Jonathan J ^c   Schanstra, Joost P ^e,f   Brand, Korbinian ^g   Kuczyk, Markus A ^g   Mischak, Harald ^a,d   Vlahou, Antonia ^b   Theodorescu, Dan ^h,i   Merseburger, Axel S ^g  

^a MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e INSERM   (France)

^f UNIVERSITÉ PAUL SABATIER   (France)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Diagnosis; Protease prediction; Proteomics; Renal cell carcinoma; Urinary peptide markers

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) GAMMA; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CALGRANULIN B; CATHEPSIN; CD99 ANTIGEN; COLLAGEN; COLLAGEN ALPHA1 CHAIN; COLLAGEN ALPHA2; FIBRINOGEN; FIBRINOGEN ALPHA; FIBRINOGEN BETA; KALLIKREIN; PEPTIDE; PROTEINASE; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BODY MASS; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; FEMALE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY DISEASE; MALE; MASS SPECTROMETRY; METASTASIS; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SMOKING; URINALYSIS; VALIDATION STUDY; VERY ELDERLY;

DIAGNOSIS; PROTEASE PREDICTION; PROTEOMICS; RENAL CELL CARCINOMA; URINARY PEPTIDE MARKERS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDES;

EID: 84891910260     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.12.010     Document Type: Article

References (68)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2013, 63:11-30.
2. Zini L., Perrotte P., Jeldres C., Capitanio U., Duclos A., Jolivet-Tremblay M., et al. A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses. BJU Int 2009, 103:899-904.
3. Van Poppel H., Da Pozzo L., Albrecht W., Matveev V., Bono A., Borkowski A., et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011, 59:543-552.
4. Ljungberg B., Bensalah K., Bex A., Canfield S., Dabestani S., Hofmann F., et al. Guidelines on renal cell carcinoma Mar 2013, European Association of Urology (EAU), Arnhem (The Netherlands), [56 pp.].
5. Merseburger A.S., Kuczyk M.A. Value of targeted therapies for renal cell cancer. Urologe A 2008, 47:1303-1310.
6. Grunwald V., Merseburger A.S. The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors - is there more to come?. Eur J Cancer 2013, 49:2504-2511.
7. Grunwald V., Merseburger A.S. Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. Onco Targets Ther 2012, 5:111-117.
8. National Cancer Institute Report of the kidney/bladder cancers progress review group, August 2002 2012, BiblioGov, [91 pp.].
9. Cairns P. Renal cell carcinoma. Cancer Biomark 2011, 9:461-473.
10. Fliser D., Novak J., Thongboonkerd V., Argiles A., Jankowski V., Girolami M.A., et al. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007, 18:1057-1071.
11. Rossing K., Mischak H., Dakna M., Zürbig P., Novak J., Julian B.A., et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008, 19:1283-1290.
12. Grossman H.B., Soloway M., Messing E., Katz G., Stein B., Kassabian V., et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006, 295:299-305.
13. Theodorescu D., Wittke S., Ross M.M., Walden M., Conaway M., Just I., et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006, 7:230-240.
14. Theodorescu D., Schiffer E., Bauer H.W., Douwes F., Eichhorn F., Polley R., et al. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl 2008, 2:556-570.
15. AJCC cancer staging manual 2002, Springer, New York. 6th ed. F.L. Greene (Ed.).
16. Haubitz M., Dhaygude A., Woywodt A. Mechanisms and markers of vascular damage in ANCA-associated vasculitis. Autoimmunity 2009, 42:605-614.
17. Alkhalaf A., Zürbig P., Bakker S.J., Bilo H.J., Cerna M., Fischer C., et al. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010, 5:e13421.
18. Delles C., Schiffer E., von Zur Muhlen C., Peter K., Rossing P., Parving H.H., et al. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens 2010, 28:2316-2322.
19. Schiffer E., Vlahou A., Petrolekas A., Stravodimos K., Tauber R., Geschwend J.E., et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res 2009, 15:4935-4943.
20. Metzger J., Negm A.A., Plentz R.R., Weismuller T.J., Wedemeyer J., Karlsen T.H., et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 2013, 62:122-130.
21. Wittke S., Mischak H., Walden M., Kolch W., Radler T., Wiedemann K. Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. Electrophoresis 2005, 26:1476-1487.
22. Mischak H., Vlahou A., Ioannidis J.P. Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin Biochem 2013, 46:432-443.
23. Neuhoff N., Kaiser T., Wittke S., Krebs R., Pitt A., Burchard A., et al. Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 2004, 18:149-156.
24. Coon J.J., Zurbig P., Dakna M., Dominiczak A.F., Decramer S., Fliser D., et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2008, 2:964.
25. Stalmach A., Albalat A., Mullen W., Mischak H. Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis 2013, 34:1452-1464.
26. Decramer S., Wittke S., Mischak H., Zürbig P., Walden M., Bouissou F., et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 2006, 12:398-400.
27. DeLeo J.M. Receiver operating characteristic laboratory (ROCLAB): software for developing decision strategies that account for uncertainty. Second International Symposium on. Uncertainty Modeling and, Analysis 1993, 318-325.
28. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 1995, 57:125-133.
29. Kuznetsova T., Mischak H., Mullen W., Staessen J.A. Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. Eur Heart J 2012, 33:2342-2350.
30. Zürbig P., Renfrow M.B., Schiffer E., Novak J., Walden M., Wittke S., et al. Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006, 27:2111-2125.
31. Klein J., Eales J., Zurbig P., Vlahou A., Mischak H., Stevens R. Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally occurring peptide generation. Proteomics 2013, 13:1077-1082.
32. Mischak H., Allmaier G., Apweiler R., Attwood T., Baumann M., Benigni A., et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010, 2:46ps2.
33. Minamida S., Iwamura M., Kodera Y., Kawashima Y., Tabata K., Matsumoto K., et al. 14-3-3 protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid. Anal Bioanal Chem 2011, 401:245-252.
34. Kaya K., Ayan S., Gokce G., Kilicarslan H., Yildiz E., Gultekin E.Y. Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma. Scand J Urol Nephrol 2005, 39:25-29.
35. Rogers M.A., Clarke P., Noble J., Munro N.P., Paul A., Selby P.J., et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003, 63:6971-6983.
36. Good D.M., Thongboonkerd V., Novak J., Bascands J.L., Schanstra J.P., Coon J.J., et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res 2007, 6:4549-4555.
37. Rossing K., Mischak H., Rossing P., Schanstra J.P., Wiseman A., Maahs D.M. The urinary proteome in diabetes and diabetes-associated complications: new ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2008, 2:997-1007.
38. Pozzi A., Zent R. Integrins, extracellular matrix, and terminal differentiation of renal epithelial cells. J Am Soc Nephrol 2008, 19:1043-1044.
39. Lochter A., Navre M., Werb Z., Bissell M.J. alpha1 and alpha2 integrins mediate invasive activity of mouse mammary carcinoma cells through regulation of stromelysin-1 expression. Mol Biol Cell 1999, 10:271-282.
40. Xiao B., Ma L.L., Zhang S.D., Xiao C.L., Lu J., Hong K., et al. Correlation between coagulation function, tumor stage and metastasis in patients with renal cell carcinoma: a retrospective study. Chin Med J (Engl) 2011, 124:1205-1208.
41. Du J., Zheng J.H., Chen X.S., Yang Q., Zhang Y.H., Zhou L., et al. High preoperative plasma fibrinogen is an independent predictor of distant metastasis and poor prognosis in renal cell carcinoma. Int J Clin Oncol 2013, 18:517-523.
42. Sarach M.A., Rovasio R.A., Eynard A.R. Platelet factors induce chemotactic migration of murine mammary adenocarcinoma cells with different metastatic capabilities. Int J Exp Pathol 1993, 74:511-517.
43. Poggi A., Vicenzi E., Cioce V., Wasteson A. Platelet contribution to cancer cell growth and migration: the role of platelet growth factors. Haemostasis 1988, 18:18-28.
44. Belloc C., Lu H., Soria C., Fridman R., Legrand Y., Menashi S. The effect of platelets on invasiveness and protease production of human mammary tumor cells. Int J Cancer 1995, 60:413-417.
45. Lewalle J.M., Castronovo V., Goffinet G., Foidart J.M. Malignant cell attachment to endothelium of ex vivo perfused human umbilical vein. Modulation by platelets, plasma and fibronectin. Thromb Res 1991, 62:287-298.
46. Felding-Habermann B., O'Toole T.E., Smith J.W., Fransvea E., Ruggeri Z.M., Ginsberg M.H., et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001, 98:1853-1858.
47. Jones D.S., Wallace A.C., Fraser E.E. Sequence of events in experimental metastases of Walker 256 tumor: light, immunofluorescent, and electron microscopic observations. J Natl Cancer Inst 1971, 46:493-504.
48. Labelle M., Hynes R.O. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov 2012, 2:1091-1099.
49. Olas B., Wachowicz B., Mielicki W.P. Cancer procoagulant and blood platelet activation. Cancer Lett 2001, 169:165-171.
50. Honn K.V., Cavanaugh P., Evens C., Taylor J.D., Sloane B.F. Tumor cell-platelet aggregation: induced by cathepsin B-like proteinase and inhibited by prostacyclin. Science 1982, 217:540-542.
51. Zheng G., Martignoni G., Antonescu C., Montgomery E., Eberhart C., Netto G., et al. A broad survey of cathepsin K immunoreactivity in human neoplasms. Am J Clin Pathol 2013, 139:151-159.
52. Argani P., Hicks J., De Marzo A.M., Albadine R., Illei P.B., Ladanyi M., et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol 2010, 34:1295-1303.
53. Merseburger A.S., Hennenlotter J., Simon P., Ohneseit P.A., Kuehs U., Kruck S., et al. Cathepsin D expression in renal cell cancer-clinical implications. Eur Urol 2005, 48:519-526.
54. Tan Ide A., Ricciardelli C., Russell D.L. The metalloproteinase ADAMTS1: a comprehensive review of its role in tumorigenic and metastatic pathways. Int J Cancer 2013, 133:2263-2276.
55. Zielinski V., Brunner M., Heiduschka G., Schneider S., Seemann R., Erovic B., et al. ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study. BMC Cancer 2012, 12:76.
56. Jiang C., Zhang Y., Yu H.F., Yu X.T., Zhou S.J., Tan Y.F. Expression of ADAM8 and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Tumour Biol 2012, 33:2167-2172.
57. Jin J.S., Chen A., Hsieh D.S., Yao C.W., Cheng M.F., Lin Y.F. Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int J Surg Pathol 2006, 14:65-72.
58. Sanders A.J., Webb S.L., Parr C., Mason M.D., Jiang W.G. The type II transmembrane serine protease, matriptase-2: possible links to cancer?. Anticancer Agents Med Chem 2010, 10:64-69.
59. Bergum C., Zoratti G., Boerner J., List K. Strong expression association between matriptase and its substrate prostasin in breast cancer. J Cell Physiol 2012, 227:1604-1609.
60. Wu S.R., Cheng T.S., Chen W.C., Shyu H.Y., Ko C.J., Huang H.P., et al. Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am J Pathol 2010, 177:3145-3158.
61. Gabril M., White N.M., Moussa M., Chow T.F., Metias S.M., Fatoohi E., et al. Immunohistochemical analysis of kallikrein-related peptidases in the normal kidney and renal tumors: potential clinical implications. Biol Chem 2010, 391:403-409.
62. Douglas M.L., Richardson M.M., Nicol D.L. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma. Cancer 2004, 100:2118-2124.
63. Pflug B.R., Zheng H., Udan M.S., D'Antonio J.M., Marshall F.F., Brooks J.D., et al. Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett 2007, 246:139-148.
64. Weissinger E.M., Metzger J., Dobbelstein C., Wolff D., Schleuning M., Kuzmina Z., et al. Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation. Leukemia 2013, [ahead of print].
65. Good D.M., Zurbig P., Argiles A., Bauer H.W., Behrens G., Coon J.J., et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010, 9:2424-2437.
66. Zurbig P., Jerums G., Hovind P., Macisaac R.J., Mischak H., Nielsen S.E., et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012, 61:3304-3313.
67. Klein J., Lacroix C., Caubet C., Siwy J., Zurbig P., Dakna M., et al. Fetal urinary peptides to predict postnatal outcome of renal disease in fetuses with posterior urethral valves (PUV). Sci Transl Med 2013, 5:198ra06.
68. Small D.M., Burden R.E., Jaworski J., Hegarty S.M., Spence S., Burrows J.F., et al. Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization. Int J Cancer 2013, 133:2102-2112.